Synthesis and evaluation of lipoic acid - donepezil hybrids for Alzheimer's disease using a straightforward strategy

被引:2
|
作者
Luzet, Vincent [1 ]
Allemand, Florentin [2 ]
Richet, Chloe [2 ]
Dehecq, Barbara [3 ]
Bonet, Alexandre [3 ]
Harakat, Dominique [4 ]
Refouvelet, Bernard [5 ]
Martin, Helene [3 ]
Cardey, Bruno [2 ]
Pudlo, Marc [3 ]
机构
[1] Univ Franche Comte, FEMTO ST, F-25000 Besancon, France
[2] Univ Franche Comte, CNRS, UMR6249, Chrono Environm, F-25000 Besancon, France
[3] Univ Franche Comte, INSERM, UMR RIGHT, EFS, F-25000 Besancon, France
[4] URCATech, CNRS, UMR 7312, ICMR, URCA Bat 18,BP 1039, F-51687 Reims 2, France
[5] Univ Franche Comte, INSERM, UMR 1322, LINC, F-25000 Besancon, France
关键词
Donepezil; Lipoic acid; Acetylcholinesterase; Antioxidant; Neuroprotection; Alzheimer disease; ACETYLCHOLINESTERASE; FLUORESCEIN; DERIVATIVES; LIGANDS; DRUGS;
D O I
10.1016/j.bmcl.2024.129938
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease is associated with a progressive loss of neurons and synaptic connections in the cholinergic system. Oxidative stress contributes to neuronal damages and to the development of amyloid plaques and neurofibrillary tangles. Therefore, antioxidants have been widely studied to mitigate the progression of Alzheimer's disease, and among these, lipoic acid has demonstrated a neuroprotective effect. Here, we present the synthesis, the molecular modelling, and the evaluation of lipoic acid-donepezil hybrids based on O-desme- thyldonepezil. As compounds 5 and 6 display a high inhibition of acetylcholinesterase (IC50 = 7.6 nM and 9.1 nM, respectively), selective against butyrylcholinesterase, and a notable neuroprotective effect, slightly better than that of lipoic acid, the present study suggests that O-desmethyldonepezil could serve as a platform for the straightforward design of donepezil hybrids.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Alzheimer's disease: Launch of a study with donepezil
    Neel, David
    REVUE NEUROLOGIQUE, 2006, 162 (11) : 1160 - 1160
  • [42] Donepezil: Tolerability and safety in Alzheimer's disease
    Pratt, RD
    Perdomo, CA
    Surick, IW
    Ieni, JR
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (09) : 710 - 717
  • [43] Donepezil for the treatment of agitation in Alzheimer's disease
    Howard, Robert J.
    Juszczak, Edmund
    Ballard, Clive G.
    Bentham, Peter
    Brown, Richard G.
    Bullock, Roger
    Burns, Alistair S.
    Holmes, Clive
    Jacoby, Robin
    Johnson, Tony
    Knapp, Martin
    Lindesay, James
    O'Brien, John T.
    Wilcock, Gordon
    Katona, Cornelius
    Jones, Roy W.
    DeCesare, Julia
    Rodger, Michaela
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (14): : 1382 - 1392
  • [44] Evaluation of the effect of donepezil on cerebral blood flow velocity in Alzheimer's disease
    Ghorbani, Abbas
    Chitsaz, Ahmad
    Shishegar, Mehdi
    Akbari, Mojtaba
    NEUROSCIENCES, 2010, 15 (03) : 172 - 176
  • [45] Donepezil: An anticholinesterase inhibitor for Alzheimer's disease
    Shintani, EY
    Uchida, KM
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (24) : 2805 - 2810
  • [46] Donepezil in patients with severe alzheimer’s disease
    Karen Marder
    Current Neurology and Neuroscience Reports, 2006, 6 (5) : 363 - 364
  • [47] Donepezil for dementia due to Alzheimer's disease
    Birks, Jacqueline S.
    Harvey, Richard J.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (06):
  • [48] Transdermal donepezil on the treatment of Alzheimer's disease
    Sozio, Piera
    Cerasa, Laura S.
    Marinelli, Lisa
    Di Stefano, Antonio
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 361 - 368
  • [49] Donepezil for severe Alzheimer's disease - Reply
    Winblad, Bengt
    LANCET, 2006, 368 (9533): : 362 - 362
  • [50] Donepezil and very mild Alzheimer's disease
    不详
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2010, 14 (01) : 30 - 30